OSENI clinical study results
In all clinical trials, OSENI was coadministered as alogliptin and pioglitazone.
10 In patients on background metformin, OSENI achieved greater A1C reductions than pioglitazone alone at week 26*
Significantly more patients achieved A1C ≤7.0% with OSENI compared to pioglitazone and alogliptin alone*
Individual results may vary.
*In a 26-week, double-blind study, 1554 patients already on metformin (median dose 1700 mg) were randomized to one of 12 once-daily treatment groups: placebo; 12.5 mg or 25 mg of alogliptin alone; 15 mg, 30 mg, or 45 mg of pioglitazone alone; or 12.5 mg or 25 mg of alogliptin in combination with 15 mg, 30 mg, or 45 mg of pioglitazone. The primary endpoint was A1C reduction from baseline with the coadministration of alogliptin and pioglitazone compared to pioglitazone alone at week 26. Results for reductions in A1C reflect an adjusted least squares mean value. 4,10
† P≤0.001 vs pioglitazone and alogliptin alone.
‡ P≤0.01 vs pioglitazone and alogliptin alone.
In a study of patients inadequately controlled on diet and exercise, OSENI 25/30 mg provided powerful A1C reductions
Patients achieved a –1.0% change (mean baseline 8.8%; n=160) from baseline with alogliptin 25 mg, a –1.2% change (mean baseline 8.8%; n=153) with pioglitazone 30 mg, and a –1.7% change (mean baseline 8.8%; n=158;
P<0.01 vs individual comparators) from baseline with OSENI 25/30 mg. §10 In the same study, significantly more patients achieved A1C ≤7.0% with OSENI compared to pioglitazone and alogliptin alone
In a study of patients inadequately controlled on diet and exercise, 63%
|| (n/N=103/164) of patients achieved A1C ≤7.0% with OSENI 25/30 mg vs 24% (n/N=40/164) with alogliptin 25 mg and 34% (n/N=55/163) with pioglitazone 30 mg. §10
Individual results may vary.
In a 26-week, double-blind, active-controlled study, 655 patients with type 2 diabetes inadequately controlled on diet and exercise alone were randomized to receive alogliptin 25 mg alone, pioglitazone 30 mg alone, coadministration of alogliptin 12.5 mg and pioglitazone 30 mg, or alogliptin 25 mg and pioglitazone 30 mg once daily. Primary endpoint was the change in A1C from baseline with the coadministration of alogliptin 25 mg with pioglitazone 30 mg vs individual component regimens alone at week 26. Results for A1C reductions reflect an adjusted least squares mean value. § 5,10
|| P≤0.01 vs pioglitazone and alogliptin alone.
Safety and tolerability profile for OSENI
Review safety profile for OSENI
Important Safety Information for NESINA, KAZANO, and OSENI
WARNING: CONGESTIVE HEART FAILURE—for OSENI
Thiazolidinediones, including pioglitazone, which is a component of OSENI, cause or exacerbate congestive heart failure in some patients.
After initiation of OSENI, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone in OSENI must be considered.
OSENI is not recommended in patients with symptomatic heart failure.
Initiation of OSENI in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated.
WARNING: LACTIC ACIDOSIS—for KAZANO
Lactic acidosis is a rare, but serious complication that can occur due to metformin accumulation. The risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic impairment, renal impairment, and acute congestive heart failure.
The onset is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. Laboratory abnormalities include low pH, increased anion gap, and elevated blood lactate.
If acidosis is suspected, KAZANO should be discontinued and the patient hospitalized immediately.
NESINA, KAZANO, and OSENI are contraindicated in patients with a history of serious hypersensitivity reaction to any of the components of these products, such as anaphylaxis, angioedema, or severe cutaneous adverse reactions.
KAZANO is contraindicated in patients with renal impairment (e.g., serum creatinine levels ≥1.5 mg/dL for men, ≥1.4 mg/dL for women or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia.
KAZANO is contraindicated in patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis.
Do not initiate OSENI in patients with established NYHA Class III or IV heart failure.
Warnings and Precautions—for KAZANO
Lactic acidosis: Warn against excessive alcohol intake. KAZANO is not recommended in hepatic impairment and is contraindicated in renal impairment. Ensure normal renal function before initiating and at least annually thereafter. Temporarily discontinue in patients undergoing radiologic studies with intravascular iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Lactic acidosis due to metformin accumulation during therapy is fatal in approximately 50% of cases. The risk increases in patients with renal impairment, congestive heart failure requiring drug treatment, and with increasing age.
Vitamin B12 deficiency: Metformin may lower Vitamin B12 levels. Monitor hematologic parameters annually.
Warnings and Precautions—for OSENI
Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure. Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. Monitor patients for signs and symptoms.
Edema: Dose-related edema may occur. Use with caution in patients with edema.
Fractures: Increased incidence in female patients. Apply current standards of care for assessing and maintaining bone health.
Bladder cancer: Data suggest an increased risk of bladder cancer in pioglitazone users. Data also suggest that the risk increases with duration of use. Do not use OSENI in patients with active bladder cancer. Use caution when using in patients with a prior history of bladder cancer. Tell patients to promptly report any sign of hematuria or other symptoms such as dysuria or urinary urgency as these may be due to bladder cancer.
Macular edema: Macular edema has been reported in some patients taking pioglitazone. Recommend regular eye exams. Instruct patients to report any visual changes promptly.
Ovulation: Therapy with pioglitazone may result in ovulation in some premenopausal anovulatory women.
Warnings and Precautions—for NESINA, KAZANO, and OSENI
Acute pancreatitis: There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue NESINA, KAZANO, or OSENI.
Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with alogliptin such as anaphylaxis, angioedema or severe cutaneous adverse reactions. In such cases, promptly discontinue NESINA, KAZANO, or OSENI, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. Use caution in a patient with a history of angioedema with another DPP-4i because it is unknown whether such patients will be predisposed to angioedema.
Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded. Baseline liver test panel is recommended. If liver injury is detected, promptly interrupt NESINA, KAZANO, or OSENI and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart NESINA, KAZANO, or OSENI if liver injury is confirmed and no alternative etiology can be found. Use with caution in patients with hepatic impairment.
Hypoglycemia: Insulin and insulin secretagogues are known to cause hypoglycemia. A lower dose of the insulin or insulin secretagogue may be required to minimize the risk when used in combination with NESINA, KAZANO, or OSENI.
Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with NESINA, KAZANO, OSENI, or any other anti-diabetic drug.
Most common adverse reactions (≥4% of patients treated with NESINA 25 mg and more frequently than in patients who received placebo) were nasopharyngitis (4.4%), headache (4.2%), and upper respiratory tract infection (4.2%).
Most common adverse reactions (≥4% of patients treated with co-administration of alogliptin and metformin) were upper respiratory tract infection (8.0%), nasopharyngitis (6.8%), diarrhea (5.5%), hypertension (5.5%), headache (5.3%), back pain (4.3%), and urinary tract infection (4.2%).
Most common adverse reactions (≥4% of patients treated with co-administration of alogliptin and pioglitazone) were nasopharyngitis (4.9%), back pain (4.2%), and upper respiratory tract infection (4.1%).
Use of OSENI with CYP2C8 strong inhibitors (e.g., gemfibrozil) will, or inducers (e.g., rifampin) may, require dose adjustment.
Cationic drugs eliminated by renal tubular secretion should be used with caution if taken with KAZANO.
NESINA (alogliptin), KAZANO (alogliptin and metformin HCl), and OSENI (alogliptin and pioglitazone) are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. NESINA, KAZANO, and OSENI are not for treatment of type 1 diabetes or diabetic ketoacidosis.
Please see the full
Prescribing Information, including Medication Guide, for NESINA.
Please see the full Prescribing Information, including Medication Guide, for KAZANO.
Please see the full Prescribing Information, including Medication Guide, for OSENI.
American Diabetes Association. Standards of medical care in diabetes–2013.
Diabetes Care. 2013;36:S11-S66. NESINA (alogliptin) Prescribing Information. Takeda Pharmaceuticals.
Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
Int J Clin Pract. 2009;63:46-55. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
J Clin Endocrinol Metab. 2012;97:1615-1622. Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.
Diabetes Care. 2010;33:2406-2408. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 010 Group. Efficacy and safety of dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
Diabetes Care. 2008;31:2315-2317. KAZANO (alogliptin and metformin HCl) Prescribing Information. Takeda Pharmaceuticals.
Data on file. Takeda Pharmaceuticals.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Diabetes Care. 2012;35:1364-1379. OSENI (alogliptin and pioglitazone) Prescribing Information. Takeda Pharmaceuticals.
NESINA, KAZANO, and OSENI are trademarks of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.
©2014 Takeda Pharmaceuticals U.S.A., Inc.
This site is intended for use by U.S. residents only.